What Enosium Life Science does

Enosium Life Science is a Paris-headquartered European scientific services group founded in January 2024 by Dr. Antoine Amer with financial backing from Otium Capital, a French private investment firm with approximately €1.5 billion in assets under management specializing in Buy & Build strategies. The group serves pharmaceutical, biotechnology, and medical technology companies across Europe, providing consulting services spanning the healthcare product value chain. Following three strategic acquisitions completed in October 2024 (Inbeeo for market access and pricing strategy, Vyoo Agency for health economics and HEOR, and the Epione group comprising KPL Paris, Alinéa Plus, and Sirius Customizer for medical affairs and scientific communication) and the April 2025 acquisition of Rweality for real-world evidence and health technology assessment, Enosium operates through six retained-brand subsidiaries alongside five integrated service pillars: Clinical Research (CRO), Regulatory Affairs, Market Access & Health Economics, Medical Affairs, and Marketing & Commercial Strategies.

The business model is professional services revenue. Each subsidiary maintains its own client relationships and brand identity while benefiting from group synergies, shared commercial resources, and coordinated business development by senior leaders including the CEO and Head of Medico-Marketing and Business Development. Pricing is custom and project-based, with multi-year contract cadences typical of enterprise healthcare engagements; no public pricing tiers or per-unit economics are disclosed. The group targets enterprise pharmaceutical, biotech, and medtech clients, and revenue is generated through project-based engagements and retainer contracts. The underlying technology stack is intentionally lean — value derives primarily from human expertise, with no proprietary platform or technology product at the core. The May 2025 partnership with UK-based Page & Page Health provides access to PIRL, an AI-powered insights tool that supports strategic decision-making and communication across engagements.

Following the October 2024 acquisitions, consolidated revenue reached approximately €15 million with a team of approximately 70 employees; the April 2025 integration of Rweality expanded headcount further. The group's stated strategic ambition is to reach several hundred million euros in revenue within five years through continued external growth. Enosium does not use resellers or intermediaries and operates through direct enterprise sales across the European market.

Name

Enosium Life Science

Legal name

Advisantis Consulting SARL

Website

https://enosium.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Enosium Life Science is a Paris-based European scientific services group that provides consulting in clinical research, regulatory affairs, market access, medical affairs, and marketing to pharmaceutical, biotech, and medtech companies, built through a Buy & Build acquisition strategy.

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting Services

NAICS

Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690), Professional, Scientific, and Technical Services (541)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

akta.pro secondary industries

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL), Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO), Healthcare & Life Sciences PR (MPAAADAD)

Keywords

• Clinical research services
• Market access consulting
• Health economics research
• Regulatory affairs consulting
• Medical affairs services

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Scientific Consulting Services: Enosium Life Science generates revenue through providing specialized scientific consulting services to pharmaceutical, biotech and medtech companies across five core areas: clinical research (CRO), regulatory affairs, market access and health economics, medical affairs, and marketing. Services include strategic advisory, clinical studies, medical writing, biostatistics, market access strategy, pricing strategy, scientific communication, and marketing campaign development. Revenue is generated through project-based engagements and retainer contracts with healthcare industry clients.
2. Subsidiary Service Revenue: Each subsidiary (Inbeeo, Vyoo Agency, KPL Paris, Sirius Customizer, Alinéa Plus, Rweality) provides specialized services that contribute to the group's consolidated revenue. Each operates with its own client relationships while benefiting from group synergies and commercial resources.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Enosium Life Science is a European scientific services group that delivers specialized consulting across the healthcare product value chain for pharmaceutical, biotech, and medtech companies. Its offering spans five integrated pillars — clinical research (CRO), regulatory affairs, market access & health economics, medical affairs, and marketing — delivered through six wholly-owned subsidiaries (Inbeeo, Vyoo Agency, KPL Paris, Sirius Customizer, Alinéa Plus, Rweality) operating across France, the UK, and broader Europe.

Product overview

Enosium Life Science is a European integrated scientific services group offering a portfolio of complementary subsidiaries and five core service pillars covering the entire healthcare product value chain. The group comprises six acquired specialized companies: Inbeeo (market access/pricing strategy), Vyoo Agency (health economics/HEOR), KPL Paris (medical affairs), Sirius Customizer (strategic consulting/patient journey), Alinéa Plus (scientific events/publishing), and Rweality (real-world evidence/HTA). These subsidiaries operate alongside five integrated service pillars: Clinical Research (CRO), Regulatory Affairs, Market Access & Health Economics, Medical Affairs, and Marketing & Commercial Strategies. The model combines local expertise with international reach, serving pharmaceutical, biotech, and MedTech industries across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

• Inbeeo Market access and pricing strategy consulting for pharmaceutical and MedTech companies in Europe, using a data-driven approach to define, communicate, and optimize innovation value from clinical development through lifecycle management.
• Vyoo Agency Health economics and outcomes research (HEOR) consultancy providing cost-effectiveness and budget impact analyses using advanced modeling tools to compare and prioritize medical strategies based on clinical benefit and economic efficiency.
• KPL Paris Medical affairs consultancy in France dedicated to developing and executing tailored medical and medico-marketing strategies, including data analysis, medical education, KOL management, digital transformation, and patient experience optimization.
• Sirius Customizer Strategic consulting firm for the health, pharma, and MedTech sectors, providing care pathway optimization, market access strategies, public affairs, and communication through a network of experts.
• Alinéa Plus Scientific events and medical publishing specialist with over 20 years of experience, offering tailored solutions for in-person, digital, and hybrid events and collaborating with scientific societies.
• Rweality Real-world evidence (RWE) and health technology assessment consultancy providing end-to-end solutions including RWE generation, market access and pricing strategy, HEOR, organizational impact on healthcare systems, and field market access operations.
• Clinical Research (CRO) Clinical research services spanning Phase III through real-world studies and early access programs, including clinical studies, medical writing, biostatistics, real-world data, and early access expertise for pharmaceutical and biotech clients.
• Regulatory Affairs Regulatory strategy, submission, pharmacovigilance, quality assurance, and regulatory compliance services for healthcare products across European markets.
• Market Access & Health Economics Access strategy, HEOR, pricing and reimbursement, value-based healthcare, and public affairs services designed to optimize market access and demonstrate product value to payers and health systems.
• Medical Affairs Medical strategy, scientific communication, data generation, and medical education/training services to support medical stakeholders and drive evidence-based healthcare decisions.
• Marketing & Commercial Strategies Brand strategy, communication campaigns, multi-channel marketing, market research, and go-to-market and commercial excellence services for pharmaceutical and healthcare products.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Five partnerships are on record, tiered flagship and core.

• Page & Page HealthflagshipStrategic or Co-development Partner · 12 May 2025Strategic partnership announced May 12, 2025 between Enosium Life Science and UK-based Page & Page Health. The alliance combines scientific, strategic, creative, and commercial expertise to provide end-to-end solutions for pharmaceutical, biotech, and medtech companies throughout the product lifecycle. Key element is access to PIRL, Page & Page Health's AI-powered insights tool. The partnership enables earlier value articulation in product lifecycles and provides clients with integrated support from clinical development through commercialization.
• RwealitycoreOthers · 1 April 2025Rweality was acquired by Enosium Life Science in April 2025. It is a consulting firm specializing in real-world evidence and health technology assessment. Rweality brings expertise in market access, pricing strategy, health economics (HEOR), organizational impact on healthcare systems, and field market access operations. The acquisition strengthens Enosium's capabilities in healthcare data valuation and market access services.
• InbeeocoreOthers · 3 October 2024Inbeeo is a leading consulting firm specializing in market access and pricing strategies for pharmaceutical drugs and medical devices in Europe. Specializes in data-driven approaches to help define, communicate, and optimize the value of innovations from clinical development to lifecycle management.
• Vyoo AgencycoreOthers · 3 October 2024Vyoo Agency is one of the few companies highly specialized in health economics and outcomes research (HEOR). Provides cost-effectiveness and budget impact analyses using advanced modeling tools to compare and prioritize medical strategies based on clinical benefit and economic efficiency.
• Epione Group (KPL, Alinéa Plus, Sirius Customizer)coreOthers · 3 October 2024Epione Group comprises three entities: KPL (French specialist in medical affairs and medico-marketing strategies), Alinéa Plus (expert in scientific events and medical publishing with over 20 years of experience), and Sirius Customizer (strategic consulting for care pathway optimization and market access). The group brings expertise in medical communication, scientific events, and patient journey optimization.

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• SGS SA: Swiss-based testing, inspection, and certification giant with a life sciences division offering CRO and consulting services. Similar Buy & Build DNA applied across life sciences services, with greater scale and global footprint.
• IQVIA: Global leader in clinical research, real-world evidence, and life sciences consulting. IQVIA competes with Enosium's CRO and market access pillars at the enterprise scale Enosium aspires to reach, and serves the same pharma/biotech client base.
• Syneos Health: Biopharma solutions organization combining CRO services with commercial and medical affairs capabilities. Closely mirrors Enosium's combined CRO + Medical Affairs + Marketing pillars, serving the same pharmaceutical clients.
• Parexel International: Global CRO and biopharmaceutical services provider offering clinical research, regulatory, and market access services. Competes with Enosium across multiple pillars and serves the same European pharma client base.
• Eurofins Scientific: European-headquartered life sciences services conglomerate built through aggressive M&A. Comparable to Enosium's PE-backed Buy & Build strategy applied to life sciences services, though at much larger scale.
• ICON plc: Major global CRO offering clinical research, laboratory, and consulting services. Directly comparable to Enosium's Clinical Research pillar and competes for the same enterprise pharma clients across Europe.
• Charles River Laboratories: Major life sciences services platform offering CRO, research models, and consulting services. A benchmark for what a mature, scaled life sciences services roll-up can become — relevant peer for Enosium's growth trajectory.

Direct peers

• ZS Associates: Global consulting firm specializing in pharmaceutical sales, marketing, and market access strategy. Directly competes with Enosium's Market Access and Commercial Strategies pillars for pharma client engagements.
• Pharmalex (PharmaLex): European-headquartered regulatory affairs and pharmacovigilance consulting firm, also built through PE-backed roll-up strategy. Most directly comparable peer to Enosium, competing in regulatory affairs, market access, and quality compliance.

Others

• Page & Page Health: UK-based healthcare communications agency and Enosium's strategic partner. Provides communications, creative, and PIRL AI insights capabilities to Enosium clients; adjacent service provider rather than competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/enosium

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enosium Life Science